Alder Biopharmaceuticals prepares to ramp up hiring effort

Following a $40 million venture round in January, Seattle-based Alder Biopharmaceuticals has plans to ramp up its antibody work and will hire a number of new researchers. In a move to boost its staff from 34 to about 50, the biotech is searching for workers skilled at antibody manufacturing and clinical development. That's all good news for the Seattle area, where the biotech scene has been the center of more downsizing than upsizing in recent years.

- read the report in the Seattle Times

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.